Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb
Hepatitis C virus (HCV) is a major cause of chronic hepatitis and liver carcinoma and new therapies based on novel targets are needed. The tight junction protein claudin 1 (CLDN-1) is essential for HCV cell entry and spread, and anti-CLDN-1 rat and mouse mAbs are safe and effective in preventing and...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Published: |
Microbiology Society
2016
|
| Online Access: | https://eprints.nottingham.ac.uk/40138/ |